샤페론

378800KOSDAQ

56.0 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40

News Sentiment20.0 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 7.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Shapieron is a biotech venture specializing in drug development, leveraging its platform targeting GPCR19 to inhibit inflammatory complexes. The company is conducting clinical trials for COVID-19 and Alzheimer's treatments, while expanding into ADC and RPT-based nanobody development. It has established a U.S. subsidiary and demonstrated commercialization capabilities through two technology transfers.

Number of Employees

53people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.95Industry Average 1.204.0Point

In line with industry avg

ROE

-76.22Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

4.65Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲547.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼9.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -70.9% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 5Neutral 0Negative 1Average Sentiment Score 80

Positive
샤페론, 액면병합 절차 착수…오는 29일 변경상장 예정
샤페론의 액면병합 절차로 인해 글로벌 사업 확장과 기술이전이 가속화되어 긍정적인 시장 반응이 예상됩니다.
Positive
샤페론 자회사 니즈테크, 싱가포르 유통망 구축…글로벌 사업 확대
샤페론 자회사 니즈테크의 싱가포르 법인 설립으로 글로벌 시장 진출 확대가 예상되어 긍정적 영향.
Positive
샤페론, 아토피 치료제 ‘누겔’ 日 특허 등록…"글로벌 기술이전 속.....
샤페론의 아토피 치료제 누겔이 일본에서 제형 특허를 획득하여 글로벌 시장 진출에 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 510Won52-week high 2,95552-week low 409

1-month return5.0Point

1m +7.37% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-09-01
Neutral반기보고서 (2026.06)2026-08-12
Neutral주요사항보고서(자기전환사채만기전취득결정)2026-08-11